A5047332501- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Esophageal Cancer Research and Treatment
- Prenatal Screening and Diagnostics
- Liver Diseases and Immunity
- Cancer-related gene regulation
- Vascular anomalies and interventions
- Advanced Clustering Algorithms Research
- Ubiquitin and proteasome pathways
- Cancer therapeutics and mechanisms
- Obesity and Health Practices
- Urinary and Genital Oncology Studies
- Click Chemistry and Applications
- Head and Neck Cancer Studies
- CAR-T cell therapy research
- Dietetics, Nutrition, and Education
- Computational Drug Discovery Methods
- Childhood Cancer Survivors' Quality of Life
- Pancreatitis Pathology and Treatment
- Assisted Reproductive Technology and Twin Pregnancy
- Congenital Heart Disease Studies
University of Michigan
2023
Bristol-Myers Squibb (United States)
2018-2022
University of Pittsburgh
2015-2018
This phase 1/2a, open-label study (NCT02419417) evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of BMS-986158, a selective bromodomain extraterminal domain (BET) inhibitor. Dose escalation was performed with 3 BMS-986158 dosing schedules: A (5 days on, 2 off; range, 0.75-4.5 mg), B (14 7 2.0-3.0 C (7 14 2.0-4.5 mg). Eighty-three patients were enrolled received ≥1 dose. Diarrhea (43%) thrombocytopenia (39%) most common treatment-related adverse events (TRAEs)....
Circulating levels of the placental glycoprotein hormone human chorionic gonadotropin (hCG) are higher in women carrying female v . male fetuses; yet, significance this difference with respect to maternal factors, environmental exposures and neonatal outcomes is unknown. As a first step evaluating biologic clinical sex differences hCG, we conducted population-level analysis assess its stability across subgroups. Subjects were singleton pregnancies who participated prenatal newborn screening...
Increased serum bile acids (BAs) have been observed in patients with non-alcoholic steatohepatitis (NASH). Pegbelfermin (PGBF), a polyethylene glycol-modified (PEGylated) analogue of human fibroblast growth factor 21 (FGF21), significantly decreased hepatic steatosis and improved fibrosis biomarkers metabolic parameters NASH phase IIa trial. This exploratory analysis evaluated the effect PGBF on BAs explored potential underlying mechanisms.Serum 7α-hydroxy-4-cholesten-3-one (C4) were...
Abstract Although hematuria (blood in urine) is the most common symptom of bladder cancer, 70–98% cases are benign. These patients unnecessarily undergo costly, invasive, and expensive evaluation for cancer. Therefore, there remains a need noninvasive office‐based tests that can rapidly reliably rule out cancer undergoing evaluation. Herein, clinical assay matrix metalloproteinases (“Ammps”) presented, which generates visual signal based on collagenase activity (in urine patients) Ammps...
Objective The most accurate noninvasive parameter to predict whether a patient with aortic coarctation will meet interventional criteria at catheterization remains elusive. We aim determine the best independent echocardiographic predictors of peak-to-peak pressure gradient ≥20 mm Hg catheterization, accepted threshold for intervention. Design Retrospective query our database from 1/2007 7/2016 diagnostic code was performed. Multiple measurements and blood gradients prior cardiac were...
Abstract Background: BMS-986158 is a potent, selective, and orally bioavailable small-molecule inhibitor of the bromodomain extraterminal (BET) family transcription modulators being evaluated in patients with various tumors phase 1 clinical study (NCT02419417). An integrated PK/PD analysis leveraging PK, biomarker, safety data from was performed to support dose schedule (Sch) selection further studies BMS-986158. Methods: Five doses (0.75-4.5 mg) 3 dosing regimens (Sch A: 5 days on, 2 off...
Although next-generation sequencing assays are routinely carried out using samples from cancer trials, the data not always of required quality. There is a need to evaluate performance tissue collection sites and provide feedback about quality data. This study used modeling approach based on whole exome control (QC) metrics relative participating in Bristol Myers Squibb Immuno-Oncology clinical trials sample collection. We identified several events for swap. Overall, most performed well few...
Abstract Background: Tumor inflammation has been associated with response to nivolumab (NIVO) in patients cancer. In squamous cell carcinoma of the head and neck (SCCHN), tumor tissue samples can be assessed inflammatory gene expression signature scores determined by profiling (GEP); however, availability may limited. We evaluated association between scores, GEP using blood or samples, NIVO. Methods: post-hoc analyses, was performed RNA-seq on pre- (D1) on-treatment (D43) whole pretreatment...
TNBC is more likely to metastasize within 3-5 years than other forms of breast cancer and has a median survival 17.6-21.3 months after metastasis. Recent advances are promising, but trial results immunotherapy-chemo combinations have resulted in 3-year overall rate under 36% PD-L1 based cohort. There thus an unmet need for innovations that lead new treatments improve outcomes patients with personalized manner. We developed platform identify predictors drug efficacy TNBC. assembled panel...
<h3>Background</h3> Despite significant improvements in treatment outcomes with ICIs, deeper understanding is needed to improve for patients melanoma who experience no clinical benefit from ICI therapy and exhibit early disease progression (primary resistance).<sup>1</sup> We analyzed translational factors using data 9 BMS-sponsored trials of nivolumab (NIVO), ipilimumab (IPI) their combination advanced cutaneous (CheckMate 003, 037, 038, 064, 066, 067, 069, 511, 742) predict resistance ICIs...